JCVI Awarded 5 Year, Approximately $25 Million NIH Grant to Establish GCID
News Jun 07, 2014
Scientists from the J. Craig Venter Institute (JCVI) have been awarded a five year grant from the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) to establish and operate a Genome Center for Infectious Diseases (GCID). Funding for this Center is up to $25 million over the 5 year award period.
The goal of the grant is to further develop and enhance basic science understanding of infectious diseases by increased focus on and analysis of the pathogens responsible for infectious disease. The findings and outcomes from the work will be available as a resource for the broad scientific community.
The research, led by JCVI co- principal investigators, Karen Nelson, Ph.D., President and William Nierman, Ph.D., Professor, Infectious Disease Group, will involve more than 50 collaborators at approximately 40 research organizations around the world.
Infectious diseases are still one of the leading causes of death worldwide, especially in children in Africa and Southeast Asia. Globally, anti-microbial drug resistance continues to rise with some of the most common bacteria resistant to all but the strongest classes of antibiotics. The world population is also growing and travel is easier and faster to all corners of the world making pandemics a continual threat. Continued research into pathogen biology and infectious disease transmission is a key component to helping to alleviate these global health challenges.
Since the inception of JCVI, pathogen genomics has been a major focus. JCVI was a past recipient of funding as one of NIAID’s Microbial Sequencing Centers and Genomic Sequencing Centers for Infectious Diseases. Building on this experience, the JCVI-led team will utilize next generation DNA sequencing technologies, coupled with new bioinformatics and computing capabilities to meet the new GCID goals. The overarching objective of the program is to apply these genomic technologies to better understand pathogen biology, virulence, drug resistance, immune evasion, and host microbiome biological interactions. Specific aims of the program are:
• Enhance understanding of pathogen drug resistance and identify approaches to manage human infections by drug resistant organisms.
• Gain new insight into microbial diversity and evolution of pathogen populations and how these impact human infectious diseases.
• Identify mechanisms and consequences of pathogen modulation of host response to infection, and understand how the pathogen interacts with host immune system and the host microbiome.
• Characterize the genomic variation in and virulence of infectious diseases.
• Explore human immunity to malaria and influenza.
To achieve these specific targets, the program will be broken down into three research projects which will focus on viruses, bacteria and parasites. Other JCVI researchers working on this grant include: Mark Adams, Ph.D., Scientific Director; Granger Sutton, Ph.D., Professor, Informatics and Suman Das, Ph.D., Assistant Professor, Infectious Disease Group.
“Since the earliest days of the Institute, pathogen genomics and infectious disease research has been one of our key focus areas given the grave health and economic toll infectious diseases take on societies globally,” said J. Craig Venter. Ph.D., Founder and CEO, JCVI. “We are very pleased to be the recipients of this major grant from NIAID and look forward to enabling a more in-depth understanding of pathogen biology and potentially aiding in better treatments and preventative measures against infectious disease,” he concluded.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018